- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Interventions
- Not listed
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Glen Oaks, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 74
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Obesity
- Interventions
- IHBG-10, Placebo
- Dietary Supplement
- Lead sponsor
- Avera McKennan Hospital & University Health Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Sioux Falls, South Dakota
- Conditions
- Schizophrenia, Type 2 Diabetes Mellitus
- Interventions
- Risperidone, Olanzapine
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2006
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Schizophrenia
- Interventions
- LY2140023, Olanzapine, Aripiprazole, Risperidone, Quetiapine
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • Escondido, California • Garden Grove, California + 39 more
- Conditions
- Schizophrenia
- Interventions
- CX516 (Ampakine)
- Drug
- Lead sponsor
- North Suffolk Mental Health Association
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 105 participants
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Psychoses
- Interventions
- Not listed
- Lead sponsor
- Genomas, Inc
- Industry
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Hartford, Connecticut • Lexington, Kentucky
- Conditions
- Psychotic Disorders
- Interventions
- Aripiprazole or Perphenazine, Metformin, Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 8 Years to 19 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Glen Oaks, New York • Chapel Hill, North Carolina
- Conditions
- Schizophrenia
- Interventions
- AVE1625, placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Interventions
- olanzapine, risperidone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 31
- States / cities
- Little Rock, Arkansas • Escondido, California • Garden Grove, California + 28 more
- Conditions
- Antipsychotic-induced Weight Gain (AIWG)
- Interventions
- Miricorlilant, Placebo
- Drug
- Lead sponsor
- Corcept Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 40
- States / cities
- Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 33 more
- Conditions
- Stroke
- Interventions
- Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,234,412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Titusville, New Jersey
- Conditions
- Schizophrenia
- Interventions
- Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Psychotic Disorders, Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorders
- Interventions
- quetiapine, olanzapine, risperidone
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Schizophrenia
- Interventions
- paliperidone, risperidone, haloperidole, perphenazine, aripiprazole, quetiapine, paliperidone palmitate, olanzapine
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 55
- States / cities
- Bullhead City, Arizona • Tuscon, Arizona • Little Rock, Arkansas + 52 more
- Conditions
- Schizophrenia
- Interventions
- risperidone, olanzapine
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 18 Years to 60 Years
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Schizophrenia, Diabetes, Metabolic Syndrome, Hyperglycemia
- Interventions
- olanzapine, risperidone
- Drug
- Lead sponsor
- Nathan Kline Institute for Psychiatric Research
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bipolar Disorder
- Interventions
- Ketogenic foodstuffs, Standard of Care Oral antipsychotics, Standard of care long acting injectable medication for bipolar disorder
- Dietary Supplement · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Montgomery, Alabama
- Conditions
- Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases
- Interventions
- EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Placebo, Antipsychotic therapy
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Wichita, Kansas
- Conditions
- Schizophrenia
- Interventions
- LY2140023, aripiprazole, olanzapine, risperidone
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 11
- States / cities
- Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Schizophrenia
- Interventions
- Risperidone plus Placebo, Risperidone plus DMXB-A
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Schizophrenia, Psychotic Disorders
- Interventions
- Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 337 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2019
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Risperidone, Olanzapine, Quetiapine, Aripiprazole
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 28
- States / cities
- Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
- Conditions
- Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
- Interventions
- Olanzapine, risperidone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 16 Years to 40 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 24
- States / cities
- Stanford, California • Miami, Florida • Atlanta, Georgia + 21 more
- Conditions
- Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
- Interventions
- risperidone, quetiapine, olanzapine, divalproex
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia